Abstract 14312: Addition of Home Blood Pressure Measurement and Biomarkers for the Detection of Concentric Hypertrophy
Background: Concentric hypertrophy is a phenotype of hypertensive cardiac organ damage and an independent predictor of cardiovascular disease. The aim of this study was to determine whether the measurement of home blood pressure (BP) and biomarkers provides additional information for the identification of concentric hypertrophy.
Methods: In 1,370 participants (mean age 65.5±11.2 years) with one or more cardiovascular risk factors from the J-HOP (Japan Morning Surge_Home Blood Pressure) study, we evaluated a screening strategy for concentric hypertrophy determined by echocardiography with home BP level and two biomarkers, N-terminal pro-brain-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin T (Hs-cTnT), and and excluded the patients with left ventricular dysfunction (ejection fraction < 50%).
Results: In the multivaliate model, home systolic BP (Odds ratio [OR]=1.02, 95% confidence interval [CI] =1.01-1.03, P<0.001), log transformed NT-proBNP (OR=2.15, 95%CI=1.50-3.08, P<0.001) and log transformed Hs-cTnT (OR=1.73, 95%CI=1.02-2.96, P=0.044) were independently associated with the presence of concentric hypertrophy after adjusting covariates. The percentage of patients with concentric hypertrophy was 22.3% (n=305). The area under the receiver operator characteristic curve for the discrimination of concentric hypertrophy improved from 0.675 (95% CI, 0.641-0.708) for the baseline model that included the conventional risk factors and clinic BP level to 0.694 (95% CI, 0.661-0.727) for the inclusion of home BP level, and to 0.714 (95%CI, 0.682-0.747) for the inclusion of NT-proBNP and Hs-cTnT.
Conclusion: The measurement of both the home BP level and two biomarkers can provide additional information for the detection of concentric hypertrophy.
- © 2013 by American Heart Association, Inc.